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Poly(ADP-ribose) polymerase-1 (PARP-1) is an important novel target in cancer therapy. This enzyme is essential in the repair
of single-stranded breaks in DNA via the base excision repair pathway. Drugs which inhibit PARP are emerging as a promising
new class of anticancer agents particularly eﬀective against tumors which have lost homologous recombination (HR) through
loss of functional BRCA1 and BRCA2. PARP inhibitors potentially represent a major breakthrough for patients with hereditary
BRCA-associatedcancers.Furthermoretheirroleinsporadicepithelialovariancancerisemergingwithidentiﬁcationofadditional
subpopulations of women who may beneﬁt a priority. This paper will summarize the mechanism of action of PARP inhibition and
its role in the treatment of BRCA1- and 2-associated cancers. We will then expand on the broader relevance and future directions
for PARP inhibition in the clinical setting.
1.Introduction
Epithelial ovarian cancer (EOC) is the ﬁfth leading cause of
death in women in North America [1]. Despite the eﬃcacy
of platinum-based chemotherapy, over 75% of women with
stage III/IV EOC ultimately relapse and die from their
disease. Median survival for women whose disease does not
respond or in whom duration of response is short is less
than 12 months [2]. Traditional cytotoxics topotecan and
liposomal doxorubicin demonstrate only modest eﬃcacy in
women with platinum resistant EOC and are associated with
signiﬁcant toxicity [3]. New therapeutic approaches, and the
ability to identify patients groups who will derive beneﬁt
from them, are urgently required.
Over recent years the investigation of DNA repair in
cancer cells has been a very active area of translational
research. All cells have a number of overlapping pathways
to protect the genome from DNA damage which occurs
as a result of normal cell cycling, environmental insults,
or cytotoxic chemotherapy. It is well recognized that when
mutations occur within these DNA repair pathways there
is an increased risk of malignant transformation and
chemotherapy resistance [4]. Much research has focused
on protecting cells from DNA damage and/or restoring
DNA repair function. However, emerging data suggest that
the concept of “synthetic lethality,” that is, exploiting the
vulnerability of cancer cells which have lost one mechanism
of DNA repair by targeting a second pathway, may be
a particularly attractive therapeutic approach. Poly(ADP-
r i b o s e )p o l y m e r a s e( P A R P )i sa ne n z y m ew h i c hp I a y sa n
important role in the recognition and repair of single-strand
DNA breaks via the base excision repair (BER) pathway
[5]. Over the last few years it has become apparent that
in cells which have lost BRCA1 or BRCA2, components
of a second DNA repair pathway, homologous recombi-
nation (HR), are particularly sensitive to PARP inhibition.
These data suggest that PARP inhibitors may be particu-
larly useful for the treatment of women with hereditary
BRCA1/2-associated EOC [6, 7]. Targeted therapy using
PARP inhibitors has become an important novel strategy for
treating those with hereditary ovarian cancer. Furthermore
the identiﬁcation of other subpopulations of women with
EOC who may beneﬁt from this approach is an active area
of research.2 Journal of Oncology
This paper will outline the mechanism of PARP inhibi-
tion and discuss this in relation to loss of BRCA function. We
will summarize the preclinical and clinical evidence from the
most recent studies and discuss future directions for PARP
inhibition in EOC.
2. BRCA1 andBRCA2
BRCA1 or BRCA2 mutations occur in 0.1–0.8% of the
general population and are inherited in an autosomal
dominant manner [8]. They are well recognized to have a
higher incidence in certain ethnic groups, such as women of
Ashkenazi Jewish descent [9]. Women carrying a mutation
in BRCA1 have a lifetime risk of developing ovarian cancer
of between 40 and 50%, while those carrying a BRCA2
mutation have a slightly lower risk of 10–20% [10]. Over the
past ten years, the focus of management for those identiﬁed
asBRCA1/2mutationcarriershasbeenoncancerprevention
and early cancer detection. However, despite prophylactic
measures to reduce risk of EOC, many BRCA1/2 carriers will
already have cancer at the time their mutation is diagnosed.
The BRCA1 geneis locatedon chromosome 17q21, while
BRCA2 is located on chromosome 13q12 [11, 12]. BRCA1
and BRCA2 play major roles in the repair of DNA double-
strand breaks (DSBs) by homologous recombination (HR).
HR repairs DSBs that occur in late S and G2 phase of
the cell cycle and also has a key role in repairing DSBs
that result from unrepaired single-strand break (SSB) [13].
BRCA1 signals the presence of DSBs, while BRCA2 is directly
involved in the mechanism of HR. In the absence of BRCA1
or BRCA2, alternative DNA repair pathways are used, which
resultinchromosomalinstabilityandcelldeath.Normalcells
o fc a r r i e r sa r eu s u a l l yh e t e r o z y g o t ew i t hl o s so ft h es e c o n d
allele occurring during tumorigenesis in the tumor cells of
these women [14].
Currently, the treatment of patients with BRCA-
associated EOC is identical to those with sporadic EOC.
However,evenpriortotheemergenceofthePARPinhibitors,
data suggested that cancers associated with BRCA mutations
responded diﬀerently to chemotherapy [15]. Tan et al.
compared 22 BRCA-positive patients with EOC to 44
nonhereditary EOC controls in a matched case-control
study. They found that BRCA-positive patients have higher
response rates to ﬁrst line platinum-based treatment (81.8%
versus 43.2%, P = .004), subsequent lines of platinum-based
treatments (second line, 91.7% versus 40.9%, P = .004),





There are currently 17 members of the PARP superfamily
identiﬁed [17]. PARP-1 is the most studied enzyme, which
is involved in the repair of SSBs of DNA by the base
excision repair (BER) pathway [5]. Targeting the nuclear
enzyme PARP-1 represents a new and novel approach to the
treatment of EOC and appears to be particularly promising
for those carrying mutations in the BRCA1 and 2 genes [14].
Cells utilize several overlapping DNA repair mechanisms
to maintain the integrity of the genome. PARP-1 activation
occurs in response to metabolic, chemical, or radiation-
induced DNA SSBs and forms part of the BER pathway
[18, 19]. PARP-1 detects and signals the presence of an SSB
by binding to DNA adjacent to the damage. Once bound,
PARP-1 catalyzes the cleavage of the coenzyme nicotinamide
adenine dinucleotide (NAD+) into nicotinamide and ADP-
ribose to produce highly negatively charged branched chains
of poly(ADP-ribose) (PAR). A multiprotein repair complex
is then formed including repair enzymes DNA ligase III,
the DNA polymerase pol B, and scaﬀolding proteins such
as XRCC1 (X-ray repair cross-complementing 1). Following
ADP-ribosylation, PARP-1 has reduced aﬃnity for DNA and
is released. After repair, the PAR polymers are degraded via
poly(ADP-ribose) glycohydrolase (PARG) [14]( Figure 1).
The role of PARP-1 may not be limited to just SSB repair;
roles in the DSB repair response have also been proposed
[20].
The new generation of PARP inhibitors inhibits PARP by
competitive inhibition of NAD+. In the preclinical setting,
PARP-1 inhibitors enhance the cytotoxic eﬀects of ionizing
radiation and cytotoxic chemotherapy [21]. Additionally, in
the preclinical setting, the use of PARP-1 inhibitors as single
agents did not cause any measurable toxicity, but the combi-
nationofPARP-1inhibitorwithtemozolomideinthetumor-
bearing mice caused signiﬁcant toxicity [22]. There did not
seem to be a correlation, however, between the antitumor
activityandthetoxicityofthePARPinhibitor-temozolomide
combinations, suggesting that toxicity and chemosensiti-
zation were by diﬀerent mechanisms. While promising in
combination with other agents, PARP inhibitors appear to
be particularly potent in patients who have defects in DNA
repair.
In a normal cell, PARP-1 inhibition leads to failure of
SSB repair, resulting in the formation of a DSB in the
DNA when a replication fork encounters the SSB. Thus
the DSB can be repaired by HR and the ﬁdelity of the
genome maintained. However, in cells carrying defects in
BRCA1/2, HR is defective, resulting in an attempted repair
of the DSB by the more error prone nonhomologous end
joining (NHEJ) pathway [18]. As a result, the cell acquires
lethal levels of damage and cellular viability is lost, a prime
example of “synthetic lethality” with the malignant cell able
tofunctionwiththelossofoneDNArepairmechanism(HR)
but ceasing to be viable with the loss of a second (BER)
[23, 24]. As most BRCA1/2 carriers have one normal allele,
the hope was that inhibition of PARP would be selective for
tumor cells.
In 2005, two preclinical papers demonstrated the sen-
sitivity of BRCA1- and BRCA2-deﬁcient cell lines to
PARP inhibition [6, 7]. The ﬁrst paper by Bryant et al.
demonstrated reduced survival of BRCA2-deﬁcient cell lines
with four PARP inhibitors. They concluded that BRCA2-
deﬁcient cells were sensitive to PARP inhibition, and that
monotherapy with one of these agents could selectively














Once bound to damaged
DNA, PARP modifies itself
producing large branched
chains of PAR 
Figure 1: The role of PARP in the repair of single-strand DNA breaks via the base excision repair pathway.
demonstrated how both BRCA1- and BRCA2-deﬁcient cells
lines were sensitive to inhibition of PARP-1, and that BRCA2
deﬁcient cells were more than 1000 times more sensitive
to nanomolar concentrations of PARP inhibitor [7]. Both
of these papers demonstrated how homozygotes (tumor
cells) are sensitive to the mechanism of PARP inhibition;
whereas heterozygotes (the rest of the patient’s cells) are
insensitivetothismechanismandshouldnotexhibittoxicity.
These ﬁndings from two independent groups using diﬀerent
chemical classes of PARP inhibitors on diﬀerent BRCA-
deﬁcient cell lines were the ﬁrst to suggest the potent eﬀect
of PARP inhibition.
4. ClinicalEvidenceinPhase Iand IITrials
A number of PARP inhibitors have entered the clinic in
both intravenous and oral formulations. The four which
are furthest along in terms of development are AGO14699
(Pﬁzer), AZD2281 (AstraZeneca), ABT-888 (Abbott), and
BSI-201 (BI Par), and all four of these compounds demon-
strate profound inhibition of PARP-1.
Olaparib (AZD2281, KU- 0059436, AstraZeneca) is
an oral small-molecule PARP inhibitor. The ﬁrst clinical
evidence demonstrating the sensitivity of BRCA-mutated
cancers to PARP inhibitor monotherapy was presented in
a study by Yap et al. in 2007 [25]. This phase I trial
included 44 patients, of which 11 patients had a BRCA
mutation associated cancer. Dose escalation was guided
by toxicity, pharmacokinetic and pharmacodynamic data.
Based on the encouraging antitumor activity, many in
whom had BRCA1/2 mutations, the trial was subsequently
expanded to concentrate on cancers in patients with BRCA
mutations and was presented in 2008 by Fong et al. [26],
followed by publication of the manuscript in 2009 [27].
The drug was well tolerated in both BRCA mutated and
normal populations. Most toxicities were grade 1-2 (≥95%),
consisting of fatigue (28%), nausea (28%), vomiting (18%),
loss of taste (13%), and anorexia (12%). Grade 3-4 toxicities
were rare, consisting of myelosuppression (≤5%), nausea
and vomiting (2-3%), and dizziness or mood changes (2-
3%) [27]. Of the 60 patients that were enrolled and treated,
19 of 23 BRCA-positive carrriers were evaluable. 12 of
the 19 (63%) had a clinical beneﬁt from olaparib, with
radiologic or tumor marker responses, or stable disease
for 4 months or more [27]. Patient response was seen in
those receiving a minimum of 100mg twice daily up to
400mgtwicedaily.Responsewasthegreatestinpatientswith
platinum-sensitive disease, although duration of response
was the same regardless of the platinum-free interval
[26].
Recently data was presented from a phase II study
of olaparib in women with advanced EOC with known
mutations in BRCA1/2 [28]. Two patient cohorts received
continuous oral olaparib in 28-day cycles; 33 patients
received 400mg orally twice daily, while 24 patients received
100mg twice daily. The choice of dosing and schedule
was based on the phase I trial above [25]. The objective
response rate measured by RECIST criteria was 33% at the
400mg dose, and 12.5% at the 100mg dose, suggesting
that there may be a dose response eﬀect. The toxicity
proﬁle was mainly mild, consisting of grade 1 or 2 nausea
(44%) and fatigue (35%), with few grade 3 or 4 toxicities.
Interestingly, although numbers were low, in this study
there appeared to be a higher response rate in platinum
resistant patients (38% versus 14%), which was opposite to
that observed in the earlier phase I study (Table 1), where
response was the greatest in platinum-sensitive patients.
Laboratory studies have previously suggested that platinum
resistant patients may reacquire BRCA function [29]t h u s
potentially making them resistant to the eﬀects of PARP
inhibition. Taken together, the clinical data suggest that we
still have a lot to learn with regard to target populations
and the role of PARP inhibition. Furthermore, data from4 Journal of Oncology
Table 1: Responses rates of women with epithelial ovarian cancer to olaparib (AZD2281) by platinum sensitivity in Phase I (Fong et al.)
[26] and Phase II trials (Audeh et al.) [28].
No. evaluable Responders by RECIST (%) Responders by RECIST or GCIG (%)
Phase I [26] Phase II [28]P h a s e I [ 26] Phase II [28] Phase I [26] Phase II [28]
Total 46 33 13 (28%) 11 (33%) 21 (46%) 20 (61%)
Platinum sensitive (>6 months) 10 7 5 (50%) 1 (14%) 8 (80%) —
Platinum resistant (≤6 months) 25 26 8 (32%) 10 (38%) 11 (44%) —
Platinum refractory 11 — 0 (0%) — 2 (18%) —
the phase II study appears to give an early indication
that response (both RECIST and CA125) may be greater
in those patients with BRCA2 mutations. This would be
in line with the known mechanism of action of the two
BRCA proteins as BRCA2 plays a key role in the repair
pathway; whereas BRCA1 functions as a signaling molecule
[30]. This phase II study concluded that oral olaparib is
well tolerated and highly active in advanced, chemotherapy-
refractory BRCA-deﬁcient EOC, with greater activity seen
at a higher dose of 400mg twice daily. The optimal patient
group with respect to platinum sensitivity has not been
deﬁned.
Reassuringly in the clinical studies there does not appear
to be an increase in toxicity between BRCA mutation
carriers compared to noncarriers, supporting the theory that
PARP inhibitors should not result in increased toxicity to
heterozygote cells [6, 7].
T h e s er e c e n tp h a s eIa n dp h a s eI It r i a l sa r ep a r t i c u l a r l y
promising for patients with BRCA-associated EOC. Further
phase II trials are currently underway which will help further
elucidate the role and potential for this new targeted therapy.
5.PARPInhibitorsinSporadicOvarianCancers
BRCA-associated EOC is associated with only 10% of all
ovarian cancers. However, loss of BRCA1/2 function is not
exclusive to inheriting a mutation in the BRCA1/2 genes
[31]. The results seen in known BRCA1 and 2 mutation
carriers may also be relevant to the sporadic EOC patient
population.
Epigenetic gene inactivation is a well-recognized phe-
nomenon with 31% of EOC exhibiting aberrant methylation
of the BRCA1 promoter [32]. Furthermore, genetic or
epigenetic events occurring in other components of the HR
pathway can be found in sporadic EOC [15, 33]. These
tumors seem to be similar to BRCA1- or BRCA2-mutated
tumors, even though they do not have mutations to either
of these genes, a concept called “BRCAness.” [15, 33]. One
molecular characterization study suggested that over 50% of
patients with high-grade EOC had loss of BRCA function,
either by genetic or epigenetic events [34]. Studies have
shown that the loss of functional proteins in the HR pathway
may lead these cells to be sensitive to PARP inhibition [35].
Identiﬁcation of “BRCA-like” EOC populations who may
beneﬁt from this new therapy through the identiﬁcation
and validation of biomarkers is an active area of ongoing
research.
6. FutureDirections
At least 6 PARP inhibitors, including AG0146999 (Pﬁzer)
andMK4827(Merck),areunderinvestigationeitherassingle
agents and/or in combination with other agents or treatment
modalities. Phase II studies in women with advanced EOC
in both BRCA1/2 mutation carriers and high-grade EOC
of unknown BRCA status are ongoing, many incorporating
translational research questions which are vital to our
understanding of the biology of PARP inhibition. Currently,
olaparib is being evaluated in a randomized phase II trial
comparing this agent with pegylated liposomal doxorubicin
in patients with BRCA-mutated EOC with a platinum-free
interval of 0–12 months [36].
Early data combining PARP inhibitors with cytotoxics
suggested that the combinations may be toxic and that
substantial dose reductions of the cytotoxic agents may be
required [37]. Intriguingly, a randomized study in women
with triple negative breast cancer presented at this year’s
American Society of Clinical Oncology (ASCO) suggests that
this may not always be the case. Patients were randomized
to receive either gemcitabine 1000mg/m2 and carboplatin
AUC 2 on days 1 and 8 with or without the PARP
inhibitor BSI-201 [38]. In this study there was no diﬀerence
in the rates of toxicity or dose adjustments between the
two arms. Response rates were signiﬁcantly higher (P =
.002) for women receiving the PARP inhibitor. Currently
many combination studies are underway; the results are
awaited with interest. Combination studies in women with
both hereditary and sporadic EOC are expected in the
future.
Further deﬁning the role of PARP inhibitors in the clinic
is ongoing. Olaparib is being evaluated in a randomized
placebo-controlled trial as a maintenance therapy in patients
with sporadic EOC at high risk of early recurrence [39].
Furthermore, some suggest that PARP inhibitors could
be used to prevent cancers in patients who are BRCA




Investigation of the PARP inhibitors in the nonhered-
itary EOC population is very active with both the impact
of treatment on patients without BRCA defects and the
search for populations of women who have lost functional
proteins in the HR pathway. Investigation of PARP inhibitor
resistance and ways to overcome this resistance are emerging
ﬁelds.Journal of Oncology 5
7. Conclusions
We are living in exciting times as our knowledge of tumor
cell biology expands and new agents become available. As we
move into the era of personalized medicine, the emerging
data regarding the use of PARP inhibitors in patients
with BRCA-associated EOC are encouraging and inspiring.
Expansion and identiﬁcation of further patient groups who
will beneﬁt from this approach are a priority. Over the next
few years we expect to see an explosion in the publication of
studies exploring the use and role of PARP inhibitors in the
clinic. Careful clinical trial design, and the development and
validation of biomarkers are essential if we are to make the
optimal use of these exciting agents and improve outcome
for women with EOC.
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